comparemela.com

Latest Breaking News On - Calvin tsai - Page 1 : comparemela.com

OncoVent signs agreement with Orient EuroPharma for oregovomab

OncoVent has entered into a licence and distribution agreement with Orient EuroPharma (OEP) for the immunotherapeutic drug candidate, oregovomab.

Hong-kong
Macau
Taiwan
Cytovance-biologics
Calvin-tsai

OncoVent, a Subsidiary of Hepalink, Enters into a License and Distribution Agreement with Orient EuroPharma for the Immunotherapeutic Candidate Oregovomab

/PRNewswire/ OncoVent Co., Ltd. ("OncoVent"), a majority-controlled subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "Company"),.

Philippines
Hong-kong
Malaysia
Shenzhen
Guangdong
China
United-states
Singapore
Macau
Taiwan
Taipei
T-ai-pei

vimarsana © 2020. All Rights Reserved.